Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists.
Numerous investigators have shown that the glycoprotein IIb/IIIa integrin mediates the final common pathway in platelet aggregation which has led to development of GP IIb/IIIa receptor antagonists. This article reviews the current status of GP IIb/IIIa receptor blockade in the management of coronary artery disease, examining the results of pivotal clinical trials.
Malhotra
S
S
Department of Medicine, Safdarjang Hospital, New Delhi.
Mishra
N K
NK
Sinha
R S
RS
Gupta
B
B
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015912:Thrombolytic Therapy
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab